Previous Close | 6.45 |
Open | 6.45 |
Bid | 7.00 x 1100 |
Ask | 12.02 x 900 |
Day's Range | 6.91 - 7.06 |
52 Week Range | 4.10 - 9.76 |
Volume | |
Avg. Volume | 4,941 |
Market Cap | 93.69M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.10 |
Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.50 |
SILVER SPRING, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today provided a business update and reported financial results for the second quarter June 30, 2022. Recent Highlights Total net sales of $12.6 million, a 3.9% increase compared to $12.2 million in the second quarter of 2021 Net sales growth from existing products of 20.3%, after excluding Q2 2021 sales of discontinued product FiberCel Co-founder and boar
The regenerative medicine company has named Randy Mills, one of its co-founders, as its new president and CEO. Lloyd “is still with Aziyo and is actively assisting with that transition,” a company spokesperson confirmed Thursday to the Washington Business Journal. Since then, Aziyo co-founder Kevin Rankin, co-founder and partner of New York investment fund HighCape Capital, has also been the Maryland biotech’s executive chairman.
Provides Additional Working Capital to Further Fund Growth InitiativesSILVER SPRING, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (the “Company”), a commercial-stage regenerative medicine company announced today that it has entered into a $25 million credit facility from SWK Holdings Corporation. The new credit facility provides for an initial term loan of $21 million that the Company intends to use to fund its ongoing commercial and product development initiatives